Exelixis, Inc. - Common Stock (NQ:EXEL)

58.85 +0.46 (+0.79%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology

August 16, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis, inc (EXEL) Q2 2021 Earnings Call Transcript ↗

August 06, 2021

EXEL earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Recap: Exelixis Q2 Earnings ↗

August 05, 2021

Shares of Exelixis (NASDAQ:EXEL) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 48.00% year over year...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 05, 2021

Gainers Sensus Healthcare (NASDAQ:SRTS) ...

Via Benzinga

Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update

August 05, 2021

From Exelixis, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer ↗

August 05, 2021

The FDA has accepted Exelixis Inc's (NASDAQ: EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid...

Via Benzinga

Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

August 05, 2021

From Exelixis, Inc.

Via Business Wire

5 No-Brainer Stocks to Invest $500 In Right Now ↗

July 26, 2021

You don't need a mountain of cash to build wealth on Wall Street.

Via The Motley Fool

Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

July 22, 2021

From Exelixis, Inc.

Via Business Wire

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗

July 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...

Via Benzinga

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study ↗

July 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:...

Via Benzinga

Topics Stocks

The Smartest Stocks to Buy With $20 in July ↗

July 16, 2021

You don't need a lot of cash to begin or further your trek toward financial independence.

Via The Motley Fool

Stocks That Hit 52-Week Lows On Wednesday ↗

July 14, 2021

Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was the largest firm by market cap to set a new 52-week low....

Via Benzinga

Analyzing Exelixis's Unusual Options Activity ↗

July 12, 2021

Shares of Exelixis (NASDAQ:EXEL) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $17.64. Sentiment: BULLISH Option...

Via Benzinga

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs ↗

July 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,...

Via Benzinga

Topics Product Recall

After Plummeting More Than 23%, Is Exelixis a Buy? ↗

July 09, 2021

The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.

Via The Motley Fool

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗

July 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...

Via Benzinga

Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results? ↗

July 09, 2021

The biotech stock plunged after disappointing clinical results.

Via The Motley Fool

Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021

July 08, 2021

From Exelixis, Inc.

Via Business Wire

Fireworks Display ↗

July 05, 2021

The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked.

Via Talk Markets

End Of June ↗

June 30, 2021

Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made.

Via Talk Markets

Topics Initial Public Offering

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs ↗

June 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

June’s Best and Worst Performing Russell 1,000 Stocks ↗

June 29, 2021

The month of June, the second quarter and the first half of 2021 are almost in the bag.

Via Talk Markets

Saint Warren ↗

June 28, 2021

Today the WTI oil price rose further up over 1%.

Via Talk Markets

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗

June 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher ↗

June 28, 2021

Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04. The U.S. has...

Via Benzinga

Topics Stocks

Exelixis Stock Collapses; Can It Recover From Mixed Results In Liver Cancer Study? ↗

June 28, 2021

Exelixis reported mixed results for its advanced liver cancer treatment on Monday and EXEL stock collapsed to a seven-month low.

Via Investor's Business Daily

60 Biggest Movers From Yesterday ↗

June 29, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.